Immunologic nonresponders face increased risk of illness, but lack therapeutic options By Richard Jefferys A subset of people on antiretroviral therapy (ART) experience limited or no recovery of CD4 T-cell counts despite achieving and maintaining undetectable viral loads. Various terms…
The push for affordable HIV treatment doesn’t end with patent expirations By Tim Horn Expiry of guidelines-preferred and -alternative first-line ARTs The United States is on course for some much-needed economic relief from the crippling cost of HIV treatment, with…
The discovery of HAART and the push for evidence-based HIV treatment By Mark Harrington This is the third in a series looking back at the first two decades of TAG’s work to speed up AIDS research. In Part I: TAG’s…
Poor treatment options spur innovative research strategies By Polly Clayden, HIV i-Base Pediatric Drug Development Considerations: Pharmacokinetics There is an old adage in pediatric medicine: children are not little adults. This is particularly true when it comes to tuberculosis, for…
Gilead’s greed gives rise to a slew of advocacy priorities By Tracy Swan Activists are decrying Gilead’s refusal to continue codeveloping a winning HCV drug combination with Bristol-Myers Squibb (BMS), opting instead to focus on co-formulations of its own promising…
Preparing to defend and reshape a still-critical program By Coco Jervis An increasing demand for services, coupled with significant fiscal retrenchment among federal and state agencies, leaves the Ryan White HIV/AIDS CARE Act-funded program at a crossroads. But advocacy strategies…
By Mark Harrington Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and…
Advancing Research, Securing Access: Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and two of its insidious comorbidities, viral hepatitis and tuberculosis. Many of these challenges are inextricably intertwined, as we highlight in this issue focusing on specific clinical research and treatment-access hurdles threatening progress for all three diseases.
by Karyn Kaplan The current standard of care for HCV is pegylated interferon (PEG-IFN) and ribavirin. Yet in most countries, this treatment is unaffordable to all but the wealthiest people. In order to stimulate price reductions and increase access, Médecins…
by Erica Lessem December 28, 2012, was a historic day for the one million people around the world with strains of tuberculosis (TB) that are particularly difficult to treat. For the first time in forty years, the United States Food…